j***u
发帖数: 836 | 1 可惜，没耐心等到今天。
Exelixis (EXEL_) shares are soaring 22.7% to $4.08 on Monday after it
announced positive top of the line results for its phase 3 study in which
the company's advanced melanoma drug treatment, cobimetinib, met its primary
endpoint of a statistically significant increase in progression-free
survival compared to patients who took another treatment, Zelboraf, alone. | z**********i
发帖数: 12276 | 2 似乎市场不大，做黑色素瘤。
不懂，瞎说的。
primary
【在 j***u 的大作中提到】
: 可惜，没耐心等到今天。
: Exelixis (EXEL_) shares are soaring 22.7% to $4.08 on Monday after it
: announced positive top of the line results for its phase 3 study in which
: the company's advanced melanoma drug treatment, cobimetinib, met its primary
: endpoint of a statistically significant increase in progression-free
: survival compared to patients who took another treatment, Zelboraf, alone.
| g*********r
发帖数: 543 | | b*****r
发帖数: 2065 | 4 皮肤癌是白人种族的重大课题，这个exel前景一片大好是肯定了。 |
|
